Compare NMS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMS | ACET |
|---|---|---|
| Founded | 1993 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 83.3M |
| IPO Year | 2014 | 2017 |
| Metric | NMS | ACET |
|---|---|---|
| Price | $9.97 | $6.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $33.17 |
| AVG Volume (30 Days) | 41.2K | ★ 243.7K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $0.46 |
| 52 Week High | $12.50 | $9.97 |
| Indicator | NMS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 38.29 |
| Support Level | N/A | $6.74 |
| Resistance Level | $12.48 | $7.09 |
| Average True Range (ATR) | 0.18 | 0.76 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 35.51 | 22.90 |
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).